Pura Vida Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Pura Vida Investments’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-732,702	Closed	-$4.95M	–	129
2022 Q4	$4.95M	Sell	732,702 -100,000	-12%	-$536K	0.26%	90
2022 Q3	$12.1M	Buy	832,702 +19,874	+2%	+$278K	0.7%	44
2022 Q2	$8M	Buy	812,828 +771,435	+1,864%	+$8.51M	0.46%	58
2022 Q1	$610K	Buy	41,393 +306	+0.7%	+$4.4K	0.02%	198
2021 Q4	$544K	Buy	41,087 +19,139	+87%	+$305K	0.02%	208
2021 Q3	$383K	Buy	21,948 +1,992	+10%	+$40.4K	0.01%	257
2021 Q2	$478K	Sell	19,956 -301	-1%	-$7.88K	0.01%	202
2021 Q1	$520K	Buy	+20,257	New	+$532K	0.01%	202
2016 Q1	–	Sell	-5,714	Closed	-$290K	–	92
2015 Q4	$290K	Hold	5,714	–	–	0.12%	74
2015 Q3	$286K	Buy	5,714 +2,857	+100%	+$244K	0.16%	62
2015 Q2	$276K	Buy	+2,857	New	+$283K	0.14%	65

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Pura Vida Investments's KALV Position: Q1 2023 in Review

Pura Vida Investments sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 732,702 shares — an estimated $4.95M sold.

Pura Vida Investments first reported a position in KALV in Q2 2015 and held it in 11 quarters. The position peaked at $12.1M in Q3 2022. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Pura Vida Investments reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 732,702 KalVista Pharmaceuticals shares in Q1 2023, an estimated $4.95M.
Pura Vida Investments first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 11 quarters.
Pura Vida Investments's KalVista Pharmaceuticals position peaked at $12.1M in Q3 2022.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.